| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
As an amino acid derivative, N6-Carbobenzoxy-L-lysine N-carboxyanhydride does not have a defined primary drug target in the context of therapeutic development. However, as an NCA monomer, it is used in research to synthesize lysine-containing polypeptides for studying protein structure, drug delivery, and biomaterials. Lysine is a positively charged amino acid that plays critical roles in protein-DNA interactions, histone modification, and crosslinking. The Z protecting group allows for selective deprotection under hydrogenation conditions after polymerization. The compound can be used to synthesize poly(L-lysine) and copolymers for studying cellular uptake, gene delivery, and antimicrobial activity.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies using this compound typically involve the synthesis of polypeptides that are then evaluated in cell-based assays. Polypeptides synthesized from this NCA monomer can be used to study cellular uptake, gene delivery, and antimicrobial activity. As a lysine-containing polymer, it may interact with cell membranes through electrostatic interactions, facilitating cellular internalization. The compound can also be utilized in studies examining the role of lysine in protein-DNA interactions and as a cationic polymer for nucleic acid delivery. The Z protecting group can be removed to yield free amino groups for further functionalization. |
| ln Vivo |
In vivo studies using this compound are limited as it is primarily used as a monomer for polypeptide synthesis rather than as a therapeutic agent. However, polypeptides synthesized from this NCA monomer may be administered in animal studies to evaluate their potential as drug delivery vehicles, antimicrobial agents, or gene therapy vectors. Standard protocols involve administration via injection in rodent models, with monitoring of therapeutic efficacy, biodistribution, and safety. All animal studies must comply with institutional ethical guidelines.
|
| Enzyme Assay |
Non-cell-based assays for this compound typically involve polymerization reactions to evaluate reactivity and polymerization kinetics. Standard protocols include dissolving the NCA monomer in anhydrous solvent (e.g., DMF or DCM) and initiating polymerization with a primary amine or other initiator. The progress of polymerization is monitored by FTIR or NMR, and the resulting polymer is characterized by GPC or MALDI-TOF for molecular weight and dispersity. The Z protecting group can be removed under hydrogenation conditions (H₂/Pd) to yield deprotected poly(L-lysine). The compound's reactivity and stability are key parameters for NCA polymerization.
|
| Cell Assay |
Cell-based assays for this compound are not typically performed directly, as it is an NCA monomer used in polymer synthesis. However, the polypeptides synthesized from this monomer may be evaluated in cell-based assays to investigate their biological activities. Standard cell-based protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with synthesized polymers at varying concentrations for 24-72 hours. Cell viability, uptake, and functional responses are assessed using appropriate assays such as MTT, flow cytometry, or confocal microscopy.
|
| Animal Protocol |
In vivo animal studies for this compound are not typically performed directly, as it is a synthetic monomer rather than a therapeutic agent. However, the polypeptides synthesized from this monomer may be evaluated in animal studies for their therapeutic potential. Standard protocols involve administration via injection in rodent models, with monitoring of therapeutic efficacy, pharmacokinetics, and safety. All animal studies must comply with institutional ethical guidelines and be conducted in accordance with applicable regulations for the care and use of laboratory animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this NCA monomer are not typically studied, as it is a synthetic building block rather than a therapeutic agent. The compound is typically consumed in polymerization reactions and not administered directly in vivo. The compound shows moderate solubility in organic solvents such as DMF and DCM. It should be stored as powder at -20°C for long-term preservation. The Z protecting group is removed by hydrogenation, while the NCA ring is reactive toward nucleophiles. Definitive PK parameters are not applicable for this compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. As an NCA monomer, the compound is reactive and may cause skin and eye irritation upon contact. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound should be handled with care to avoid exposure to moisture, which can hydrolyze the NCA ring. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL).
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
N6-Carbobenzoxy-L-lysine N-carboxyanhydride is a lysine derivative featuring a Z protecting group on the ε-amino group and an NCA ring. Lysine is a positively charged amino acid that plays critical roles in protein-DNA interactions, histone modification, and crosslinking. This compound is used as a monomer in the synthesis of polypeptides via ring-opening polymerization (ROP), enabling the preparation of poly(L-lysine) and copolymers for studying cellular uptake, gene delivery, and antimicrobial activity. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C15H18N2O5
|
|---|---|
| Molecular Weight |
306.31
|
| Exact Mass |
306.121
|
| CAS # |
1676-86-4
|
| PubChem CID |
9948469
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.538
|
| LogP |
1.64
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
407
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)COC(=O)NCCCC[C@H]2C(=O)OC(=O)N2
|
| InChi Key |
HLLIDIRDRPSCHN-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C15H18N2O5/c18-13-12(17-15(20)22-13)8-4-5-9-16-14(19)21-10-11-6-2-1-3-7-11/h1-3,6-7,12H,4-5,8-10H2,(H,16,19)(H,17,20)/t12-/m0/s1
|
| Chemical Name |
benzyl N-[4-[(4S)-2,5-dioxo-1,3-oxazolidin-4-yl]butyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2647 mL | 16.3233 mL | 32.6467 mL | |
| 5 mM | 0.6529 mL | 3.2647 mL | 6.5293 mL | |
| 10 mM | 0.3265 mL | 1.6323 mL | 3.2647 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
